Lonafarnib Patent Expiration
Lonafarnib is Used for reducing the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS). It was first introduced by Sentynl Therapeutics Inc
Lonafarnib Patents
Given below is the list of patents protecting Lonafarnib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zokinvy | US7838531 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis | Jul 26, 2029 | Sentynl Theraps Inc |
| Zokinvy | US8828356 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis | Oct 17, 2025 | Sentynl Theraps Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lonafarnib's patents.
Latest Legal Activities on Lonafarnib's Patents
Given below is the list recent legal activities going on the following patents of Lonafarnib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Requirement for information sent under 37 CFR 1.750 | 08 Jul, 2024 | US7838531 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2024 | US7838531 |
| transaction for FDA Determination of Regulatory Review Period | 27 Dec, 2023 | US7838531 |
| Second letter to regulating agency to determine regulatory review period | 10 Mar, 2023 | US7838531 |
| Letter from FDA or Dept of Agriculture re PTE application | 09 Nov, 2022 | US7838531 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2022 | US7838531 |
| Initial letter Re: PTE Application to regulating agency | 23 Feb, 2022 | US7838531 |
| Patent Term Extension Application under 35 USC 156 Filed | 14 Jan, 2021 | US7838531 |
| Email Notification Critical | 11 Jan, 2021 | US7838531 |
| Change in Power of Attorney (May Include Associate POA) Critical | 11 Jan, 2021 | US7838531 |
Lonafarnib's Family Patents
